EP Patent

EP3849534B1 — Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer

Assigned to Mirati Therapeutics Inc · Expires 2025-03-05 · 1y expired

What this patent protects

Patent listed against Krazati.

Drugs covered by this patent

Krazati (ADAGRASIB) · Bristol-Myers Squibb

Patent Metadata

Patent number: EP3849534B1
Jurisdiction: EP
Classification: —
Expires: 2025-03-05
Drug substance claim: No
Drug product claim: No
Assignee: Mirati Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.